Penn State Cancer Institute led a study of over 12 million cancer patients between 2005-2015 and found that although cancer-based clinical trials may increase life expectancy, patient participation in that clinical research is extremely low. Moreover, to date, the overwhelming beneficiary of breakthrough cancer therapy-based investigational treatments tested in clinical trials are white males with private insurance who are treated at academic medical centers.
Led by Dr. Nicholas G. Zaorsky, assistant professor of radiation oncology at Penn State College of Medicine, the Penn State Cancer Institute research team accessed and analyzed over 12 million patient records involving 46 different cancer types between 2005 and 2015 in the National Cancer Database. The team found that only 11,576 (0.1%) of those patients were enrolled in clinical trials as their first course of therapy following diagnosis. The study results were published in the Journal of the National Comprehensive Cancer Network.
Dr. Niraj J. Gusani, professor of surgery at the College of Medicine and senior study author, reported that their findings—low enrollment among most ...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).